N‐glycosylation of PD‐1 promotes binding of camrelizumab
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
PD ‐1 is a highly glycosylated inhibitory receptor expressed mainly on T cells. Targeting of PD ‐1 with monoclonal antibodies ( MA bs) to block the interaction with its ligand PD ‐L1 has been successful for the treatment of multiple tumors. However, polymorphisms at N‐glycosylation sites of PD ‐1 exist in the human population that might affect antibody binding, and dysregulated glycosylation has been observed in the tumor microenvironment. Here, we demonstrate varied N‐glycan composition in PD ‐1, and show that the binding affinity of camrelizumab, a recently approved PD ‐1‐specific MA b, to non‐glycosylated PD ‐1 proteins from E. coli is substantially decreased compared with glycosylated PD ‐1. The structure of the camrelizumab/ PD ‐1 complex reveals that camrelizumab mainly utilizes its heavy chain to bind to PD ‐1, while the light chain sterically inhibits the binding of PD ‐L1 to PD ‐1. Glycosylation of asparagine 58 (N58) promotes the interaction with camrelizumab, while the efficiency of camrelizumab to inhibit the binding of PD ‐L1 is substantially reduced for glycosylation‐deficient PD ‐1. These results increase our understanding of how glycosylation affects the activity of PD ‐1‐specific MA bs during immune checkpoint therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023 · cited 1×
“The clinical application of these MAbs has greatly improved both the overall survival rate and life quality of patients with multiple tumors (Nishino et al , 2017).”
Cited by
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296341 · Cited by 216
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Metadata
- Authors
- Liu, K., Tan, S., Jin, W., Guan, J., Wang, Q., Sun, H., Qi, J., Yan, J., Chai, Y., Wang, Z., Deng, C., & Gao, G. F.
- Venue
- EMBO reports
- Published
- 2020-10-15
- Volume
- 21
- Issue
- 12
- Pages
- e51444-e51444
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- OpenAlex
- W3092655777
- Cited by
- 84
- References
- 2
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: N‐glycosylation of PD‐1 promotes binding of camrelizumab. https://app.cochat.ai/papers/10.15252/embr.202051444
- The paper
- Liu, K., Tan, S., Jin, W., Guan, J., Wang, Q., Sun, H., Qi, J., Yan, J., Chai, Y., Wang, Z., Deng, C., & Gao, G. F. (2020). N‐glycosylation of PD‐1 promotes binding of camrelizumab. EMBO reports. https://doi.org/10.15252/embr.202051444
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.